OKYO Pharma Ltd ADR (OKYO NASDAQ) stock market data APIs
$1.9341
-0.1(-5.2%)
as of February 6, 2026
Try our APIs with
free plan!
OKYO Pharma Ltd ADR Financial Data Overview
Price chart is built with
Anychart
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Prev. Close
1.9341
Open
1.8377
High
1.9928
Low
1.8367
52 wk Range
1.01-3.349
Market Cap
89 890 K
Shares Outstanding
37 611 K
EPS
-0.06
Beta
-0.184
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OKYO Pharma Ltd ADR data using free add-ons & libraries
Get OKYO Pharma Ltd ADR Fundamental Data
OKYO Pharma Ltd ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -7 089 334
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OKYO Pharma Ltd ADR News
New
OKYO Pharma Announces Successful Type C Meeting with the FDA
LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuro...
After-Hours Gainers: GH Research, Phathom, Forte, OKYO, Zai Lab, LifeMD, Werewolf & Corvus Rally
(RTTNews) - Biotech names dominated the after-hours session on Friday, with several companies posting notable gains despite limited news catalysts. GH Research PLC (GHRS) surged the most, climbing 22...
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic cor...
Nutex Health Soars 21% After Hours On Revenue Surge; Biotech Peers Join Tuesday Gainers
(RTTNews) - Several small-cap biotech and pharma names posted notable gains in Tuesday's after-hours trading session, with Nutex Health standing out as the most significant mover following its quarter...
Get OKYO Pharma Ltd ADR fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
